Long wait for pivotal data on Sanofi's oral SERD ends in failure

Sanofi’s oral selective estrogen receptor degrader (SERD) amcenestrant has flunked a pivotal trial. The failure of amcenestrant as a second-line or later treatment of ER+/HER2- advanced or metastatic breast cancer leaves Sanofi looking to studies in earlier-stage patients to rescue the potential blockbuster.